2024
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R
2011
Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy
Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy. PLOS ONE 2011, 6: e18327. PMID: 21479171, PMCID: PMC3068161, DOI: 10.1371/journal.pone.0018327.Peer-Reviewed Original ResearchConceptsMultiple drug resistanceDrug resistanceInitial treatment regimensTB control programsAnti-TB drugsDrug-resistant formsEmergence of resistanceFunctional monotherapyTreatment regimensCombination therapyTB strainsTuberculosis treatmentTherapy rangeM. tbTB bacilliMultidrug resistanceM. tuberculosisDifferent antibioticsTherapyTuberculosisInfected hostControl programsResistant formsTBMonotherapy